Gujarat Themis Biosyn Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/sy95z2v3uaiyzlgcie3qhs89.pdf

Key Takeaways


The Capacity Inflection

Sachin Patel: "We have been in a mode whereby our business has been pretty, I would say, flat, but at the same time, we've been sold out in capacity, and we have been in a working phase whereby we've been investing in capex and building the infrastructure that we have. And admittedly, we have been late by almost about a year in terms of the projects that have been implemented, but now it's all ready to go."

The MicroBiopharm Japan Acquisition

Sachin Patel: "Now with MicroBiopharm, it gives us a jump start of 7 to 8 years because all these capabilities are there, projects are there, supplies are there and of course, relationships with big pharma in Japan and a few big pharma globally also."

The Sanofi Brand Acquisition

Sachin Patel: "It essentially secures our bread and butter, which is what we are making right now."

Strategy: Fermentation-Based CDMO

Sachin Patel: "We felt that if we would be doing anything else, we will be diluting what GTBL is doing. And hence, from a perspective of GTBL, it was decided that we want to grow this particular business as a fermentation-based CDMO and not get into other businesses, which were predominantly domestic in nature."

Financial Position & Capital Structure

Sachin Patel: "We are not getting into any geography or any business where we are taking the responsibility of turning the business around. We are simply bringing in the synergies in both the places, which can add value, whereby 1 plus 1 is equal to more -- significantly more than 2."

Guidance & Commitments

CommitmentSpecificsTimeline
Expanded capacity productionManufacturing site starts full steam; fermentation capacity fully operational and running at full scaleEnd of August 2026
Revenue from expanded capacityPartial contribution from Q2 FY27; full contribution in H2Q2 FY27 / H2 FY27
MicroBiopharm Japan closingDeal closes with funding secured and optimal debt-equity mixMonth-end closing
Sanofi acquisition closingRegulatory approvals from 50+ countries; long stop date June next year6–9 months or longer
Sanofi manufacturing transition3-year TSA; all tech transfers expected complete in first yearFirst year post-closing
Hybrid power plantPhase 1 live September, Phase 2 two months later; improves EBITDA marginsSeptember / November 2026
Promoter pledge reductionExpected to go down significantlyWithin a year to 15 months
Base-case growthHigh-teen growth on base-case basisNo specific timeline given
Post-acquisition marginsClose to current GTBL margins after integration and stabilizationNo specific timeline given
MBJ enzyme commercializationFair amount of work and quick wins in synergyWithin first year

Key Metrics

MetricQ1 FY27
Revenue from operations₹43.8 crores, up 22.1% YoY from ₹35.9 crores
EBITDA₹20.8 crores, up 49.4% YoY
EBITDA margin47.5%, up 867 bps YoY
Profit after tax₹11.1 crores, up 22.1% YoY from ₹9.1 crores
Base-case growth expectationHigh-teen basis
Gross block₹435 crores in FY26 including CWIP, up from ₹62 crores in FY23
Incremental gross block added over last 3 years₹370 crores
Asset turn expectation on new fermentation and API facilities1.4x to 1.5x on ₹200 crores
Remaining base-business capex₹10–15 crores for last-mile work; total FY27 capex including maintenance around ₹20-odd crores
Fermentation capacity expansion540 KL additional capacity, fully operational by end of August
Hybrid power plant Phase 1Expected live in September, second phase 2 months later
Promoter pledge48–48.5% as of June, with 1.5–2% released in July; expected to decline significantly within 12–15 months
Sanofi portfolio13 brands across anti-TB and anti-infective segments, access to 55 countries across Europe, Middle East and Africa
Sanofi transition service agreement3 years
MicroBiopharm CDMO share of business60%
MicroBiopharm revenue split60% Japan, 40% outside Japan
MicroBiopharm formulation share4–5%, predominantly fermentation-based APIs
Equity raise plannedUp to ₹1,000 crores